A client with benign prostatic hyperplasia uses umeclidinium for COPD and now has suprapubic discomfort with inability to urinate. Which instruction should the nurse give?
1Take an extra umeclidinium dose because urinary symptoms indicate inadequate bronchodilation.
2Stop umeclidinium and contact the healthcare provider immediately before another dose.✓ Correct answer
3Restrict all fluids and wait until the next routine pulmonary appointment.
4Use an additional anticholinergic inhaler to relax the bladder outlet.
Explanation
Umeclidinium is an anticholinergic that can cause new or worsening urinary retention, particularly in clients with prostatic hyperplasia or bladder-neck obstruction. Inability to urinate with suprapubic discomfort requires immediate provider contact. The patient labeling directs clients with urinary-retention symptoms to stop the medication and call the provider before another dose. Extra anticholinergic therapy, fluid restriction, or delayed evaluation can worsen harm.
Clinical reasoning Muscarinic blockade can impair detrusor contraction and worsen bladder emptying. Prostatic obstruction increases the risk that urinary symptoms will progress to acute retention.
Decision rule New difficulty or pain with urination during umeclidinium therapy requires stopping the drug and contacting the healthcare provider immediately before another dose.
Scenario 74-year-old male with COPD and BPH on umeclidinium 62.5 mcg daily × 2 weeks. New urinary hesitancy, weak stream, sensation of incomplete emptying.
Urinary retention — Failure to empty the bladder, which can present with difficulty urinating, weak stream, painful urination, or suprapubic discomfort.
Long-acting muscarinic antagonist — An inhaled COPD maintenance drug class that can worsen urinary retention through anticholinergic effects.